Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report) shares gapped up before the market opened on Monday. The stock had previously closed at $3.80, but opened at $4.1650. Raia Drogasil shares last traded at $4.1650, with a volume of 2,465 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group raised Raia Drogasil to a “buy” rating and set a $5.20 price target for the company in a research note on Sunday. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Raia Drogasil currently has an average rating of “Moderate Buy” and an average target price of $5.20.
Read Our Latest Analysis on RADLY
Raia Drogasil Price Performance
The stock has a market capitalization of $5.49 billion and a PE ratio of 27.83. The company has a quick ratio of 0.58, a current ratio of 1.41 and a debt-to-equity ratio of 0.99. The stock’s 50 day moving average price is $3.74 and its 200-day moving average price is $3.85.
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Raia Drogasil had a net margin of 2.99% and a return on equity of 20.12%. The company had revenue of $2.17 billion for the quarter, compared to the consensus estimate of $2.32 billion. As a group, equities analysts forecast that Raia Drogasil S.A. will post 0.17 EPS for the current year.
About Raia Drogasil
Raia Drogasil SA, known as RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of drugstores under the Raia and Drogasil brands, offering prescription medicines, over-the-counter products, vitamins, personal-care items, cosmetics and other health-related merchandise.
The company also provides digital shopping and delivery services through its online channels, supporting customers with prescription fulfillment and access to pharmacy products.
Featured Articles
- Five stocks we like better than Raia Drogasil
- Tesla’s Roadster Reveal Hints at 2 Much Bigger Moves
- The AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance Anyway
- Mr. Wonderful’s Test for AI Data Center Stocks: Power, Permits, and Tenants
- Alcoa Beat Earnings, But Can It Escape the Aluminum Bears?
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
